ECO Animal Health Group (LSE:EAH) posted a solid set of half-year results for 2025, with revenue rising 19% to £39.4 million and gross margins improving to 49.6%. Growth was driven by stronger sales volumes, price optimisation, and reduced input costs, supporting an adjusted EBITDA of £3.0 million. The company also achieved a major R&D milestone, securing a Positive Opinion from the European Medicines Agency for its poultry vaccine, ECOVAXXIN® MS. This development clears a path for commercial launch in the EU in the second half of 2026 and marks meaningful progress in ECO’s innovation pipeline.

ECO Animal Health’s outlook benefits from its sound financial footing and constructive technical signals. Nevertheless, an elevated P/E ratio raises questions around valuation, and uneven revenue trends introduce some risk to forward profitability. Limited disclosure from earnings calls or corporate updates provides few additional data points.

More about Eco Animal Health

ECO Animal Health is a global veterinary pharmaceutical company specialising in treatments and vaccines for pigs and poultry. Headquartered in the UK, the business markets its products worldwide and holds regulatory approvals in more than 70 countries.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Some portions of this content may have been generated or assisted by artificial intelligence (AI) tools and been reviewed for accuracy and quality by our editorial team.